On April 16, 2026 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported that preclinical data from the Company’s next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held in San Diego, CA on April 17-22, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company has been selected to participate in a poster presentation featuring preclinical data from FT839, its next generation, 13-point edited, off-the-shelf CAR T-cell product candidate for the broad treatment of hematological malignancies and autoimmune diseases. In addition, FT839 incorporates Sword and Shield technology to evade and eliminate host allogeneic immune responses, promote functional persistence, and thereby eliminate the need for conditioning chemotherapy.
A link to the abstract can be found here: Fate AACR (Free AACR Whitepaper) Abstract Poster presentation details are as follows:
Poster Presentation
Title: FT839: A next-generation, off-the-shelf CAR T-cell uniquely engineered with a dual CAR system targeting CD19 and CD38 for the treatment of hematological malignancies and autoimmune diseases without conditioning chemotherapy
Session: CAR T-Cell Functional Enhancement
Presentation Date / Time: Tuesday, April 21, 2026 / 9:00 a.m. to Noon PDT
(Press release, Fate Therapeutics, APR 16, 2026, View Source [SID1234664433])